Earnings Call · Q3 FY2024·2024-11-06

Q3 24EPS +20.18%·Rev n/aQ2 24EPS +10.88%·Rev n/aQ1 24EPS -35.89%·Rev n/aQ4 23EPS -3.09%·Rev n/a⚠ consensus missing

Jazz Pharmaceuticals plc JAZZ

Andrea Flynn — Investor Relations

Bruce Cozadd — President and Chief Executive Officer

Renée Galá — Chief Commercial Officer

Rob Iannone — Chief Medical Officer

Phil Johnson — Chief Financial Officer

+6.8%1d on move date+6.0% vs SPY3d+14.0%5d+14.4%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more JAZZ calls or request research access.

More JAZZ calls Browse calls Request research access